Baker Bros. Advisors’s Abeona Therapeutics ABEO Stock Holding History

Baker Bros. Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-63,627	Closed	-$4.64M	–	121
2020 Q2	$4.64M	Hold	63,627	–	–	0.02%	82
2020 Q1	$3.34M	Sell	63,627 -27,902	-30%	-$1.86M	0.02%	74
2019 Q4	$7.48M	Buy	91,529 +40,000	+78%	+$2.82M	0.04%	60
2019 Q3	$2.91M	Hold	51,529	–	–	0.02%	78
2019 Q2	$6.16M	Hold	51,529	–	–	0.04%	60
2019 Q1	$9.48M	Sell	51,529 -32,598	-39%	-$5.83M	0.06%	49
2018 Q4	$15M	Sell	84,127 -3,248	-4%	-$708K	0.12%	41
2018 Q3	$28M	Hold	87,375	–	–	0.18%	33
2018 Q2	$35M	Hold	87,375	–	–	0.26%	29
2018 Q1	$31.3M	Buy	87,375 +8,000	+10%	+$2.97M	0.27%	31
2017 Q4	$31.5M	Buy	79,375 +12,000	+18%	+$4.96M	0.27%	35
2017 Q3	$28.7M	Hold	67,375	–	–	0.23%	27
2017 Q2	$10.8M	Hold	67,375	–	–	0.09%	47
2017 Q1	$8.42M	Hold	67,375	–	–	0.07%	52
2016 Q4	$8.17M	Buy	67,375 +63,308	+1,557%	+$9.91M	0.08%	53
2016 Q3	$610K	Buy	+4,067	New	+$398K	0.01%	125

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baker Bros. Advisors's ABEO Position: Q3 2020 in Review

Baker Bros. Advisors sold out of Abeona Therapeutics (ABEO) in Q3 2020, closing a stake of 63,627 shares — an estimated $4.64M sold.

Baker Bros. Advisors first reported a position in ABEO in Q3 2016 and held it in 16 quarters. The position peaked at $35M in Q2 2018. 78 funds tracked by Wall St. Rank hold ABEO as of Q3 2020.

Baker Bros. Advisors reported no remaining Abeona Therapeutics position as of Q3 2020 after selling out during the quarter.
Baker Bros. Advisors sold 63,627 Abeona Therapeutics shares in Q3 2020, an estimated $4.64M.
Baker Bros. Advisors first reported a position in Abeona Therapeutics in Q3 2016 and held it in 16 quarters.
Baker Bros. Advisors's Abeona Therapeutics position peaked at $35M in Q2 2018.
78 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2020.

Based on Baker Bros. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.